Reliance’s Strand Life Sciences has secured an Indian patent for a liquid biopsy platform aimed at early cancer detection from a blood sample. According to the company, the patent covers a cell-free DNA analysis approach that detects cancer signals using a blood test, with the goal of identifying disease at earlier stages than standard diagnostics. The reports also note that cancer continues to be diagnosed at advanced stages in many cases, and they cite estimates of more than 1.5 million new cancer cases in India each year. While the outlets agree on the patent and the general purpose of the technology—blood-based analysis of cell-free DNA for early detection—details about the specific claims of the patent and timelines for clinical rollout are not provided in the shared excerpts. The coverage presents the patent as a step in developing non-invasive diagnostic capabilities that could help support earlier diagnosis and potentially improve clinical outcomes, though the reports do not quantify performance or readiness for widespread use.